Aug 12 Albany Molecular Research Inc
said partner Bristol-Myers Squibb Co would stop
developing their experimental depression therapy.
Albany's shares tumbled 19 percent to $10.24 in afternoon
Albany said Bristol-Myers stopped two mid-stage studies of
the drug after it failed to show superiority over two other
Albany said the decision would not have an impact on its
forecasts for the third quarter and 2013.
(Reporting by Pallavi Ail in Bangalore; Editing by Saumyadeb